Rapaflo, Silodyx(silodosin)
Rapaflo, Silodosin, Silodyx, Urorec (silodosin) is a small molecule pharmaceutical. Silodosin was first approved as Rapaflo on 2008-10-08. It is used to treat prostatic hyperplasia in the USA. It has been approved in Europe to treat prostatic hyperplasia. The pharmaceutical is active against alpha-1A adrenergic receptor. In addition, it is known to target alpha-1B adrenergic receptor and alpha-1D adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Rapaflo, Silodosin (discontinued: Silodosin)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| prostatic hyperplasia | EFO_0000284 | D011470 | N40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | 3 | 4 | 7 | 4 | 19 |
| Hyperplasia | D006965 | EFO_0000536 | — | 1 | 3 | 4 | 6 | 4 | 18 |
| Ureteral calculi | D014514 | — | — | 2 | 2 | — | 3 | 2 | 8 |
| Ureterolithiasis | D053039 | EFO_1001228 | N20.1 | 2 | 2 | — | 3 | 2 | 8 |
| Calculi | D002137 | — | — | 1 | 2 | — | 2 | — | 5 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | 1 | 2 | 1 | 4 |
| Nocturia | D053158 | — | R35.1 | — | 1 | — | 1 | — | 2 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | 1 | — | 1 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney calculi | D007669 | EFO_0004253 | N20 | 1 | 2 | 2 | — | 1 | 5 |
| Urolithiasis | D052878 | — | N20-N23 | — | 2 | 1 | — | — | 3 |
| Urinary calculi | D014545 | — | — | — | 2 | 1 | — | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | 1 | — | — | 1 |
| Urination disorders | D014555 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nephrolithiasis | D053040 | — | N20.0 | 1 | 2 | — | — | 1 | 3 |
| Urinary retention | D016055 | HP_0000016 | R33 | — | 1 | — | — | 1 | 2 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 1 | — | — | — | 1 |
| Premature ejaculation | D061686 | HP_0012876 | F52.4 | — | 1 | — | — | — | 1 |
| Prostatitis | D011472 | EFO_0003830 | N41 | — | 1 | — | — | — | 1 |
| Chronic disease | D002908 | — | — | — | 1 | — | — | — | 1 |
| Pelvic pain | D017699 | — | — | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | — | 1 | 1 |
| Pathologic dilatation | D004108 | — | — | — | — | — | — | 1 | 1 |
| Trichinellosis | D014235 | EFO_0007520 | B75 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Silodosin |
| INN | silodosin |
| Description | Silodosin is an indolecarboxamide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 160970-54-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL24778 |
| ChEBI ID | — |
| PubChem CID | 5312125 |
| DrugBank | DB06207 |
| UNII ID | CUZ39LUY82 (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1A
ADRA1A
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
ADRA1B
ADRA1B
ADRA1D
ADRA1D
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Rapaflo – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Rapaflo – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Silodosin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 977 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,555 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use